Topic
ANDA Litigation
15 published works
ANDVA Advisor Blog
IRS Treatment of Litigation Costs in ANDA Cases
The Third Circuit Court of Appeals will decide whether the IRS can force Mylan (and by extension other ANDA filers) to treat a) legal expenses to prepare notice letters and…
Harness Dickey Blog
Patent Venue Construed Strictly, Even in ANDA Litigation
By Todd
In Celgene Corp. v. Mylan Pharmaceutics Inc., [2021-1154] (November 5, 2021) the Federal Circuit affirmed the dismissal of a patent infringement action against defendants, MPI and Mylan Inc., for improper…
Prosecution First Blog
Patentee’s Success Story in a Hatch-Waxman Litigation Case
By Publisher
In Tris Pharma, Inc. v. Actavis Labs. FL, Inc., 2020 WL 7028456, at *1 (D. Del. Nov. 30, 2020), the district court for the District of Delaware, on remand from…
Commercial Litigation Update
Restrictions on Venue in Hatch-Waxman Litigation
Since the enactment of the Hatch-Waxman Act in 1984, courts have held that brand companies can sue generics wherever they plan on making sales, which is everywhere in the U.S.…
Big Molecule Watch
Upcoming Webinar: Navigating Hatch-Waxman and Biologic Litigation Amid the Coronavirus Pandemic
On Thursday, April 23rd, Goodwin will be hosting a webinar, Navigating Hatch-Waxman and Biologic Litigation Amid the Coronavirus Pandemic. Join Goodwin experts, John Bennett, Elaine Blais, Srikanth Reddy and Daryl…
BioLoquitur
Innovation in Hatch-Waxman and ANDA Litigation
By Parithosh K. Tungaturthi, Ph.D.
The Hatch-Waxman Act was enacted in 1984 to address two main congressional goals: (1) to encourage innovation in pharmaceutical research and development; and (2) to help generic drugs reach the…
BioLoquitur
Now Available! Seyfarth Shaw’s Hatch-Waxman and Biosimilars Litigation: 2017 Year-in-Review
By Parithosh K. Tungaturthi, Ph.D., Dean L. Fanelli, Ph.D., Thomas A. Haag, Ph.D., Jamaica Szeliga
Seyfarth Shaw Offers Hatch-Waxman And Biosimilars Litigation: 2017 Year-in-Review Today’s rapid scientific and technological advances demand not only a thorough understanding of the complex technology, but also a meticulous application…
Delaware Intellectual Property Litigation
Judge Sleet Denies Macleods Defendants’ Motion for Judgment on the Pleadings in ANDA Action
By Memorandum Order entered by The Honorable Gregory M. Sleet in Amgen Inc. v. Macleods Pharmaceuticals, Ltd., Civil Action No. 17-817-GMS (D.Del. December 19, 2017) (consolidated), the Court denied the…
Delaware Intellectual Property Litigation
Chief Judge Stark Denies Defendants’ Motion for Reargument of Court’s Order Holding Defendants Liable for Costs of ANDA Litigation Going Forward Under Certain Conditions
By Memorandum Order entered by The Honorable Leonard P. Stark in UCB, Inc., et al. v. Watson Laboratories, Inc. et al., Civil Action No. 14-1083-LPS-SRF (D.Del., May 19, 2017), the…
Delaware Intellectual Property Litigation
Judge Andrews Grants in Part Teva’s Motion to Dismiss ANDA Complaint
By Memorandum Opinion entered by The Honorable Richard G. Andrews in Endo Pharmaceuticals Inc. et al. v. Actavis Inc. et al., Civil Action No. 14-1381-RGA (D.Del. February 8, 2017), the…